WEST LAFAYETTE, Ind., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that management will present at the following upcoming conferences:
Lazard Capital Markets 9th Annual Healthcare Conference - Tuesday, Nov. 13, at 2 p.m. EST. The conference will be held at the Pierre Hotel in New York City.
Piper Jaffray 24th Annual Healthcare Conference - Wednesday, Nov. 28, at 1 p.m. EST. The conference will be held at the New York Palace in New York City.
Webcast information can be accessed under "Events & Presentations" in the Investor Relations section of Endocyte's website at www.endocyte.com. All webcasts will be archived shortly after each live event and a replay will be available on the Company's website for 90 days following the conference.
Endocyte is a biopharmaceutical company developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging diagnostics for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging diagnostics are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
For additional information, please visit Endocyte's website at www.endocyte.com.
CONTACT: Paul Cox, Stern Investor Relations, Inc., (212) 362-1200, firstname.lastname@example.org Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, email@example.com Tony Russo, Ph.D., Russo Partners, (212) 845-4251, firstname.lastname@example.orgSource:Endocyte, Inc.